



Patent Docket P1761R1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of Ashkenazi et al.	Group Art Unit: 1646 Examiner: E. Lazar Wesley	OCT 29 2002 TECH CENTER 1600/2900
Serial No.: 09/603,866 Filed: June 26, 2000 For: Methods for Making Apo-2 Ligand Using Divalent Metal Ions		

RESPONSE

Box Non-Fee Amendment
Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

This paper is being filed in response to the Office Action mailed May 21, 2002. Entry of the amendment below and consideration of the remarks herein is respectfully requested.

IN THE CLAIMS:

Claim 1 has been amended to read:

1. (Amended) A formulation comprising Apo-2 ligand and one or more divalent metal ions consisting of the group zinc, cobalt, nickel, cadmium, magnesium, and manganese, wherein the concentration of said one or more divalent metal ions present in the formulation is at a <2X molar ratio to said Apo-2 ligand and the Apo-2 ligand comprises a polypeptide selected from the group consisting of:
 - (a) a polypeptide having amino acid residues 1 to 281 of Figure 1 (SEQ ID NO:1);
 - (b) a polypeptide having amino acid residues 114 to 281 of Figure 1 (SEQ ID NO:1);
 - (c) a fragment of the polypeptide of (a) or (b) which induces apoptosis in at least one type of mammalian cell or binds an Apo-2 ligand receptor; and